- Companies
- Infervision
Infervision Funding, Investors & Competitors
Infervision has raised $215M across 5 funding rounds, most recently a $140M Series D in July 2021.
Last Infervision funding round
$140M
Series D · Jul 2021
Cumulative funding Infervision raised
$215M
across 5 funding rounds
Key investors in Infervision
HSG
Qiming Venture Partners
Sequoia Capital
Innoangel Fund
Goldman Sachs Asset Management
New Alliance Capital
Xianghe Capital
Zhongguancun Science City Science
About Infervision
Infervision is a Beijing-based AI company applying deep learning to medical imaging for cancer diagnosis and analysis. Products include intelligent X-ray and CT aids trialed at Shanghai Changzheng Hospital, Tongji Medical College of HUST in Wuhan, and Dalian Zhongshan Hospital. Collaborations extend to Peking Union Medical College Hospital and nearly 20 other top-tier facilities in China.
Founded
2015
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Licensing, Subscription
Infervision Funding History
Infervision has raised a total of $215M across 5 funding rounds.
Infervision's first fundraising round was a $2M angel round in February 2016. The most recent completed round was a $140M Series D in July 2021.
Infervision funding rounds
| Date | Stage | Investors | Raised | Deal Summary |
|---|---|---|---|---|
| Jul 2021 | Series D | Goldman Sachs Asset Management (lead); CCB Trust; New Alliance Capital; Zhongguancun Science City Science; Z-Park Fund | $140M | InferVision is a medical artificial intelligence provider specializing in clinical applications of AI and deep learning technologies, focusing on AI-powered detection and triage systems to enhance clinician efficiency in disease prevention, control, and diagnosis. The company develops platforms for AI application management, data mining, and research, aiming to deliver advanced services to payors, providers, and patients. Founded in 2016, InferVision has launched products like the InferRead Pneumonia COVID-19 screening system, which gained adoption in hospitals globally and led to procurement by the European Union across nine countries during the pandemic. In August 2021, InferVision announced the completion of its Series D2 financing round led by Goldman Sachs Asset Management, with participation from investors including CCB Trust. The company raised around US$140 million in total across Series D1 and D2 rounds, with proceeds allocated to R&D, distribution channel expansion, and business development. Prior to this, InferVision had received over US$210 million in cumulative investments from prominent backers such as Sequoia Capital, Qiming Venture Partners, CDH Investments, and Springhill Fund. The round aligns with investor enthusiasm for AI in healthcare, particularly for accelerating medical diagnosis in large markets, as highlighted by Goldman Sachs Asset Management's managing director Xinyi Feng. InferVision's founder and chairman CK emphasized the partnership as validation of their advanced AI solutions. |
| Mar 2018 | Series B | HSG (lead); Xianghe Capital; Qiming Venture Partners | $48M | Infervision is a Beijing-based AI company specializing in medical imaging diagnosis, using deep learning for products like AI-CT for lung cancer detection via CT scans and AI-DR for cardiothoracic lesions, reducing analysis time significantly. Founded in 2016, it focuses on AI-assisted screening for diseases including lung, heart, brain, fractures, breast, and abdominal areas, with partnerships in over 150 hospitals by mid-2018 and serving about 450,000 patients. The company has expanded internationally with offices in the US, Japan, and Germany. By June 2018, its InferRead products provided 13,000 daily CT readings per hospital on average. The queried round around March 2018 appears to align with a Series B+ financing of $47 million, involving existing investors Sequoia Capital China, Qiming Venture Partners, and Genesis Capital, plus new investors Xianghe Capital and Advantech Capital. Earlier, in September 2017, Infervision raised CNY120 million (USD18 million) in a Series B led by Qiming Venture Partners with Genesis Capital and Sequoia Capital China; a prior A-round was CNY50 million in January 2017. Overall, Infervision raised over $210 million across multiple rounds by 2021, including later Series D rounds led by Goldman Sachs Asset Management and others. |
| Sep 2017 | Series B | Qiming Venture Partners (lead); Sequoia Capital | $18M | Infervision is a Chinese artificial intelligence startup focused on medical imaging. In September 2017, Qiming Venture Partners led its Series B funding round with RMB120 million (approximately US$18 million). The company has raised a total of $210.39M across 6 rounds from 22 investors, with later rounds including Series D - II for $94.94M on July 23, 2021, backed by CCB Trust, Goldman Sachs Asset Management, New Alliance Capital, and others. The firm operates in the competitive AI medical imaging space, aligned with Qiming's portfolio in AI-driven healthcare innovations like Deepwise. |
| Jan 2017 | Series A | HSG (lead) | $7M | - |
| Feb 2016 | Angel | Innoangel Fund (lead); Powercloud Venture Capital (lead) | $2M | - |
Who has invested in Infervision?
11 investors have backed Infervision across its funding rounds, including HSG, Qiming Venture Partners, Sequoia Capital, Innoangel Fund, Goldman Sachs Asset Management and New Alliance Capital.
Lead investors include Goldman Sachs Asset Management, HSG, Qiming Venture Partners, Innoangel Fund and Powercloud Venture Capital.
Infervision Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 2 | Lead | Sep 2017 | ||
| 2 | Lead | Jan 2017 | ||
| 1 | Lead | Feb 2016 | ||
| 1 | Participant | Mar 2018 | ||
| 1 | Participant | Jul 2021 | ||
| 1 | Participant | Jul 2021 | ||
| 1 | Participant | Sep 2017 | ||
| 1 | Participant | Jul 2021 | ||
| 1 | Lead | Jul 2021 | ||
This data is available for Pro users. Sign up to see all 11 Infervision investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialInfervision Competitors
Infervision competitors include listed companies like GE HealthCare, Pro Medicus and United Imaging, and private ones like Commure, Abridge and EliseAI.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Private | $200M | - | $7B | 35.0x | ||
| Private | $117M | - | $5.3B | 45.3x | ||
| Private | $100M | - | $2.2B | 22.0x | ||
| Publicly listed | $21B | $3.7B | $29B | 1.8x | ||
| Publicly listed | $186M | $147M | $13B | 62.7x | ||
| Publicly listed | $2.1B | $367M | $12B | 4.8x |
Infervision Public Comps
Infervision is still privately-owned, but its public comps include CrowdStrike, SAP, Salesforce, ServiceNow, Snowflake, Adobe, Datadog, Moody's, Nebius Group and Natera.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $4.8B | ($12M) | 51.4x | 44.5x | (19816.2x) | 151.0x | |||
| $42B | $13B | 5.8x | 5.4x | 18.4x | 17.1x | |||
| $42B | $13B | 5.5x | 5.2x | 17.8x | 12.2x | |||
| $13B | $2.6B | 11.1x | 9.6x | 57.2x | 25.0x | |||
| $4.7B | ($1.3B) | 25.6x | 21.0x | (94.1x) | 121.7x | |||
| $24B | $9.3B | 4.3x | 3.9x | 10.9x | 8.2x | |||
| $3.4B | ($588K) | 23.6x | 19.4x | (137813.0x) | 77.6x | |||
| $7.7B | $3.8B | 11.2x | 10.6x | 22.5x | 20.1x | |||
This data is available for Pro users. Sign up to see all Infervision competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Infervision
| When was Infervision founded? | Infervision was founded in 2015. |
| Where is Infervision headquartered? | Infervision is headquartered in Beijing, China. |
| Is Infervision publicly listed? | No, Infervision is a private, VC-backed company. |
| How much funding has Infervision raised? | Infervision has raised $215M across 5 funding rounds. |
| What was Infervision's last funding round? | Infervision's last funding round was a $140M Series D in July 2021, led by Goldman Sachs Asset Management. |
| Who are Infervision's investors? | Infervision's investors include Qiming Venture Partners, HSG, Innoangel Fund, Xianghe Capital, CCB Trust, New Alliance Capital, Sequoia Capital, Zhongguancun Science City Science, Goldman Sachs Asset Management, Powercloud Venture Capital and 1 other. |
| Which companies are comparable to Infervision? | Companies comparable to Infervision include Commure, Abridge, EliseAI, GE HealthCare, Pro Medicus and United Imaging. |
See companies similar to Infervision
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




